Orphagen Pharmaceuticals Presents Data on Downstream Targets of SF-1 Antagonist OR-449 at ENDO 2022
SAN DIEGO--(BUSINESS WIRE)--Orphagen Pharmaceuticals, an early-stage biopharmaceutical company focused on developing and commercializing novel therapies for cancer and other serious diseases with significant unmet need, today announced that additional data from its preclinical program to develop OR-449 for the treat...
Source: pharmiweb.com